EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi

Rhea-AI Summary

EVOQ Therapeutics announced a Collaboration and License Agreement with Sanofi (NASDAQ: SNY) on October 16, 2025 to advance EVOQ's NanoDisc technology for autoimmune diseases. Under the deal, Sanofi will lead development and worldwide commercialization while EVOQ is eligible to receive over $500 million in upfront, preclinical, development and sales milestones plus tiered royalties on product sales. The NanoDisc platform aims to restore immune tolerance across indications including celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis and lupus.

The agreement pairs EVOQ's proprietary platform with Sanofi's immunology and commercial capabilities, transferring development and market responsibilities to Sanofi and establishing milestone-driven payments and royalty economics for EVOQ.

Positive

• Deal includes over $500 million in milestone payments
• Sanofi to fund development and worldwide commercialization

Negative

• EVOQ cedes development and commercialization control to Sanofi
• EVOQ payments are milestone-based and not guaranteed

Insights

Biotech licensing strategist

Collaboration with Sanofi secures a large potential payday and global development/commercial backing for EVOQ's NanoDisc platform.

EVOQ grants a license and will collaborate on research while Sanofi takes responsibility for global development and commercialization, shifting late‑stage costs and execution risk to Sanofi. The deal includes eligibility for over $500 million in upfront, preclinical, development and sales milestones plus tiered royalties, which materially de‑risks funding needs and validates the NanoDisc approach commercially.

The primary dependencies are Sanofi's clinical development choices and execution, and the therapies' ability to demonstrate restoration of immune tolerance in human trials. Key risks include clinical failure at pivotal endpoints and the typical timeline and cost of late‑stage immunology programs. Monitor milestone triggers and any disclosed development timeline or pivotal trial start dates; the immediate horizon to watch is regulatory and clinical progression over the next few years following the October 16, 2025 announcement.

CHICAGO, Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a Collaboration and License Agreement with Sanofi, an R&D driven, AI-powered biopharma company, committed to improving people's lives and delivering compelling growth. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

EVOQ's proprietary breakthrough NanoDisc technology restores the body's natural immune tolerance pathways and opens the door for a wide range of disease-specific, curative therapies for multiple autoimmune diseases like celiac disease, type 1 diabetes, MOG (myelin oligodendrocyte glycoprotein) antibody disease, rheumatoid arthritis and lupus. Current treatments do not address the root cause of autoimmune disease which is the breakdown and failure of the body's immune tolerance systems which results in the destruction of self-tissues. 
To cure autoimmune disease, immune tolerance must be restored.

"We are truly thrilled to be collaborating with Sanofi to advance our NanoDisc technology," said David Giljohann, Ph.D., Chief Executive Officer at EVOQ. Giljohann added, "Sanofi's know-how in autoimmune disease and leadership in immunology will bring clinical development expertise and commercial presence thereby making Sanofi a highly credible and attractive partner for our technology, uniquely positioned to deliver breakthrough efficacy and convenience for patients."
Under the terms of the agreement, EVOQ and Sanofi will collaborate on research activities, Sanofi will be responsible for the development and the commercialization efforts worldwide. EVOQ is eligible to receive over $500 million in total in upfront, preclinical, development and sales milestones, as well as tiered royalties on product sales.

About EVOQ Therapeutics
EVOQ Therapeutics is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens and small molecules to restore immune tolerance. For more information, please visit www.evoqtherapeutics.com

EVOQ Therapeutics Contact:
Trevor Thompson
Ionic Advisors
trevor@ionicadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/evoq-therapeutics-announces-collaboration-and-license-agreement-with-sanofi-302585825.html

SOURCE EVOQ Therapeutics, Inc.

FAQ

What did EVOQ announce with Sanofi on October 16, 2025 (SNY)?

EVOQ announced a Collaboration and License Agreement with Sanofi (SNY) to advance its NanoDisc autoimmune therapies.

How much can EVOQ receive under the Sanofi (SNY) collaboration?

EVOQ is eligible to receive over $500 million in upfront, preclinical, development and sales milestones, plus tiered royalties.

Who is responsible for clinical development and commercialization under the EVOQ–Sanofi deal?

Sanofi will be responsible for development and worldwide commercialization of programs under the agreement.

Which autoimmune diseases does EVOQ's NanoDisc target under the Sanofi (SNY) agreement?

The NanoDisc platform targets diseases including celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis, and lupus.

Will EVOQ retain commercial rights to NanoDisc products after the Sanofi deal?

No; the agreement gives Sanofi responsibility for commercialization worldwide, while EVOQ is eligible for milestones and royalties.

Does the EVOQ–Sanofi (SNY) payment structure guarantee revenue for EVOQ?

Payments are tied to milestones and sales, so revenue depends on meeting development and commercial milestones.